These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

561 related items for PubMed ID: 29620050

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS, Hatch HL, Kosea F, Nguyen HT, Choo EF, McClure KF, Taylor TJ, Henne KR, Kuperman AV, Dombroski MA, Letavic MA.
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [Abstract] [Full Text] [Related]

  • 3. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis.
    Huang Z, Li H, Zhang Q, Tan X, Lu F, Liu H, Li S.
    Drug Des Devel Ther; 2015 Nov; 9():4319-28. PubMed ID: 26273193
    [Abstract] [Full Text] [Related]

  • 4. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X.
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
    Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C, Chi Y.
    J Hematol Oncol; 2016 Oct 04; 9(1):105. PubMed ID: 27716285
    [Abstract] [Full Text] [Related]

  • 7. A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors.
    Liu Y, Liu L, Liu L, Wang T, Guo L, Wang Y, Gao Z, Shu Y.
    Cancer Chemother Pharmacol; 2020 May 04; 85(5):907-915. PubMed ID: 32266457
    [Abstract] [Full Text] [Related]

  • 8. Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans.
    Jayaraman R, Pasha MK, Williams A, Goh KC, Ethirajulu K.
    Drug Metab Lett; 2015 May 04; 9(1):28-47. PubMed ID: 25600203
    [Abstract] [Full Text] [Related]

  • 9. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Cotreau MM, Siebers NM, Miller J, Strahs AL, Slichenmyer W.
    Clin Pharmacol Drug Dev; 2015 Mar 04; 4(2):137-42. PubMed ID: 27128217
    [Abstract] [Full Text] [Related]

  • 10. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
    Kamath AV, Chang M, Lee FY, Zhang Y, Marathe PH.
    Cancer Chemother Pharmacol; 2005 Aug 04; 56(2):145-53. PubMed ID: 15830240
    [Abstract] [Full Text] [Related]

  • 11. Prediction of Pharmacokinetic Drug-Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling.
    Bu F, Cho YS, He Q, Wang X, Howlader S, Kim DH, Zhu M, Shin JG, Xiang X.
    Drug Des Devel Ther; 2024 Aug 04; 18():4585-4600. PubMed ID: 39429896
    [Abstract] [Full Text] [Related]

  • 12. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z, Zadjura L, D'Arienzo C, Marino A, Santone K, Klunk L, Greene D, Lin PF, Colonno R, Wang T, Meanwell N, Hansel S.
    Biopharm Drug Dispos; 2005 Dec 04; 26(9):387-402. PubMed ID: 16142720
    [Abstract] [Full Text] [Related]

  • 13. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
    Choo EF, Woolsey S, DeMent K, Ly J, Messick K, Qin A, Takahashi R.
    Drug Metab Dispos; 2015 Jun 04; 43(6):864-9. PubMed ID: 25813936
    [Abstract] [Full Text] [Related]

  • 14. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
    Yang JJ, Li Y, Chakravarty A, Lu C, Xia CQ, Chen S, Pusalkar S, Zhang M, Ecsedy J, Manfredi MG, Wu JT, Shyu WC, Balani SK.
    Drug Metab Lett; 2014 Jul 04; 7(2):96-104. PubMed ID: 24484538
    [Abstract] [Full Text] [Related]

  • 15. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR, Goh E, Zeng P, New LS, Xin L, Pasha MK, Sangthongpitag K, Yeo P, Kantharaj E.
    Biol Pharm Bull; 2007 May 04; 30(5):1021-4. PubMed ID: 17473456
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V, Schuck EL, Pelletier RD, Farah N, Condon KB, Ye M, Rowbottom C, King BM, Zhang ZY, Saxton PL, Wong YN.
    Cancer Chemother Pharmacol; 2012 Jan 04; 69(1):229-37. PubMed ID: 21698359
    [Abstract] [Full Text] [Related]

  • 17. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans.
    Bauman JN, Doran AC, Gualtieri GM, Hee B, Strelevitz T, Cerny MA, Banfield C, Plotka A, Wang X, Purohit VS, Dowty ME.
    Drug Metab Dispos; 2024 Sep 16; 52(10):1124-1136. PubMed ID: 39111823
    [Abstract] [Full Text] [Related]

  • 18. Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations.
    Harrison A, Betts A, Fenner K, Beaumont K, Edgington A, Roffey S, Davis J, Comby P, Morgan P.
    Drug Metab Dispos; 2004 Feb 16; 32(2):197-204. PubMed ID: 14744941
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals.
    Hu ZY, Li XX, Du FF, Yang JL, Niu W, Xu F, Wang FQ, Li C, Sun Y.
    Acta Pharmacol Sin; 2013 Nov 16; 34(11):1437-48. PubMed ID: 24056706
    [Abstract] [Full Text] [Related]

  • 20. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV, Wang J, Lee FY, Marathe PH.
    Cancer Chemother Pharmacol; 2008 Mar 16; 61(3):365-76. PubMed ID: 17429625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.